Bumrungrad Hospital Public Company Limited (BZ7A) - Net Assets
Based on the latest financial reports, Bumrungrad Hospital Public Company Limited (BZ7A) has net assets worth €31.17 Billion EUR (≈ $36.44 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€36.46 Billion ≈ $42.62 Billion USD) and total liabilities (€5.29 Billion ≈ $6.18 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bumrungrad Hospital Public Company Limit (BZ7A) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €31.17 Billion |
| % of Total Assets | 85.5% |
| Annual Growth Rate | 8.64% |
| 5-Year Change | 76.93% |
| 10-Year Change | N/A |
| Growth Volatility | 8.98 |
Bumrungrad Hospital Public Company Limited - Net Assets Trend (2016–2025)
This chart illustrates how Bumrungrad Hospital Public Company Limited's net assets have evolved over time, based on quarterly financial data. Also explore BZ7A total assets for the complete picture of this company's asset base.
Annual Net Assets for Bumrungrad Hospital Public Company Limited (2016–2025)
The table below shows the annual net assets of Bumrungrad Hospital Public Company Limited from 2016 to 2025. For live valuation and market cap data, see market cap of Bumrungrad Hospital Public Company Limit.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €31.17 Billion ≈ $36.44 Billion |
+12.12% |
| 2024-12-31 | €27.80 Billion ≈ $32.50 Billion |
+15.37% |
| 2023-12-31 | €24.10 Billion ≈ $28.17 Billion |
+20.46% |
| 2022-12-31 | €20.01 Billion ≈ $23.39 Billion |
+13.55% |
| 2021-12-31 | €17.62 Billion ≈ $20.60 Billion |
-6.47% |
| 2020-12-31 | €18.84 Billion ≈ $22.02 Billion |
-7.05% |
| 2019-12-31 | €20.27 Billion ≈ $23.69 Billion |
+8.11% |
| 2018-12-31 | €18.74 Billion ≈ $21.91 Billion |
+12.21% |
| 2017-12-31 | €16.70 Billion ≈ $19.53 Billion |
+12.96% |
| 2016-12-31 | €14.79 Billion ≈ $17.29 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bumrungrad Hospital Public Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 131.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €29.49 Billion | 95.54% |
| Other Components | €1.38 Billion | 4.46% |
| Total Equity | €30.86 Billion | 100.00% |
Bumrungrad Hospital Public Company Limited Competitors by Market Cap
The table below lists competitors of Bumrungrad Hospital Public Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tiger Royalties and investments Plc
LSE:TIR
|
$49.33K |
|
Bangkok Bank Public Company Limited
F:BKKF
|
$49.47K |
|
Hamak Gold Ltd
LSE:HAMA
|
$49.51K |
|
Allianz Malaysia Bhd
KLSE:1163PA
|
$49.96K |
|
Coro Energy PLC
LSE:CORO
|
$49.01K |
|
Catenai PLC
LSE:CTAI
|
$48.85K |
|
Norman Broadbent Plc
LSE:NBB
|
$48.14K |
|
N4 Pharma PLC
LSE:N4P
|
$48.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bumrungrad Hospital Public Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,487,679,879 to 30,862,896,513, a change of 3,375,216,634 (12.3%).
- Net income of 7,511,763,437 contributed positively to equity growth.
- Dividend payments of 3,974,865,766 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.51 Billion | +24.34% |
| Dividends Paid | €3.97 Billion | -12.88% |
| Other Changes | €-161.68 Million | -0.52% |
| Total Change | €- | 12.28% |
Book Value vs Market Value Analysis
This analysis compares Bumrungrad Hospital Public Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €22.51 | €4.62 | x |
| 2018-12-31 | €25.32 | €4.62 | x |
| 2019-12-31 | €27.40 | €4.62 | x |
| 2020-12-31 | €23.32 | €4.62 | x |
| 2021-12-31 | €21.75 | €4.62 | x |
| 2022-12-31 | €24.79 | €4.62 | x |
| 2023-12-31 | €29.94 | €4.62 | x |
| 2024-12-31 | €34.58 | €4.62 | x |
| 2025-12-31 | €38.82 | €4.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bumrungrad Hospital Public Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.34%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.79%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.18x
- Recent ROE (24.34%) is above the historical average (21.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 25.05% | 20.24% | 0.84x | 1.47x | €2.18 Billion |
| 2017 | 24.04% | 21.50% | 0.78x | 1.43x | €2.30 Billion |
| 2018 | 22.50% | 22.66% | 0.74x | 1.34x | €2.31 Billion |
| 2019 | 18.76% | 20.29% | 0.71x | 1.31x | €1.75 Billion |
| 2020 | 6.50% | 9.74% | 0.51x | 1.31x | €-649.02 Million |
| 2021 | 7.03% | 9.76% | 0.60x | 1.21x | €-512.93 Million |
| 2022 | 25.06% | 23.83% | 0.85x | 1.23x | €2.97 Billion |
| 2023 | 29.44% | 27.61% | 0.87x | 1.23x | €4.63 Billion |
| 2024 | 28.28% | 30.23% | 0.79x | 1.19x | €5.03 Billion |
| 2025 | 24.34% | 29.79% | 0.69x | 1.18x | €4.43 Billion |
Industry Comparison
This section compares Bumrungrad Hospital Public Company Limited's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $3,837,569,670
- Average return on equity (ROE) among peers: -85.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bumrungrad Hospital Public Company Limited (BZ7A) | €31.17 Billion | 25.05% | 0.17x | $49.31K |
| China Resources Medical Holdings Company Limited (1PH) | $7.01 Billion | 3.67% | 0.95x | $428.88 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-125.88 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $720.78 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.01 Billion | -12.28% | 1.84x | $12.02 Billion |
| Fresenius Medical Care AG & Co. KGaA (FMEA) | $10.83 Billion | 11.82% | 1.22x | $11.58 Billion |
| Fresenius SE & Co. KGaA (FRE) | $3.10 Billion | 10.64% | 3.84x | $27.16 Billion |
About Bumrungrad Hospital Public Company Limited
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic,… Read more